Interpace Diagnostics Presents New Data on PancraGEN® at Digestive Disease Week
June 01 2018 - 8:30AM
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (the “Company” or
“Interpace”), a fully integrated commercial and bioinformatics
company that provides clinically useful molecular diagnostic tests
and pathology services for improved patient diagnosis and
management, announced today that the Company will be presenting new
data on the incremental value of PancraGEN® to patient outcomes
when used as a companion molecular diagnostic to traditional
imaging modalities. The results will be presented at the Digestive
Disease Week® (DDW) meeting being held in Washington, D.C. June
2nd-5th, 2018. The work being presented is entitled “Risk of
Malignancy in Pancreatic Cystic Lesions Triaged by Clinical and
Molecular Features.” Authors include Dr. James Farrell of the
Yale Center for Pancreatic Disease (presenting author), Dr. Tamas
Gonda of the Division of Digestive and Liver Disease, Columbia
University Medical Center, and Dr. Mohammad Al-Haddad of Indiana
University.
According to Syd Finkelstein, Chief Medical &
Scientific Officer of Interpace, “the results from this
collaboration with these highly regarded institutions clearly
indicates that PancraGen® provides incremental insights to
physicians as it relates to understanding their individual
patients’ risk of progressing to pancreatic cancer.” Dr.
Finkelstein continued, “these data should give physicians a high
degree of confidence in their treatment approach.” In
addition, Jack Stover, President & CEO of Interpace, stated,
“we are especially pleased to present PancraGEN® for the first time
as a companion product to traditional imaging, which we believe
provides a new method to assist physicians in making accurate
diagnoses and treatment decisions.”
About DDW
Digestive Disease Week® (DDW) is the largest international
gathering of physicians, researchers and academics in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal
surgery. Jointly sponsored by the American Association for the
Study of Liver Diseases (AASLD), the American Gastroenterological
Association (AGA) Institute, the American Society for
Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of
the Alimentary Tract (SSAT), DDW takes place June 2nd-5th at the
Walter E. Washington Convention Center in Washington, D.C. and is
expected to be attended by more than 14,000 professionals. The
meeting showcases more than 5,000 abstracts and hundreds of
lectures on the latest advances in GI research, medicine and
technology. More information can be found
at www.ddw.org.
About PancraGEN®
PancraGEN® is a molecular, pancreatic cancer
risk classifier for cysts, solid lesions, and biliary strictures
that, by using a small sample of pancreatic cyst fluid, can aid in
pancreatic cancer risk assessment. PancraGEN® is
90% accurate according to clinical studies, enabling effective risk
stratification of patients. Pancreatic cancer is often
difficult to diagnose in early stages and typically spreads rapidly
with signs and symptoms appearing when the cancer is significantly
advanced. Because of this, and that complete surgical removal of
the pancreas is not possible, pancreatic cancer is one of the
leading causes of cancer deaths.
About Interpace Diagnostics Group,
Inc.
Interpace is a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
diagnostic tests and pathology services for evaluating risk of
cancer by leveraging the latest technology in personalized medicine
for improved patient diagnosis and management. The Company
currently has four commercialized molecular tests and one test in a
clinical evaluation process (CEP); PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; ThyGenX® for
the diagnosis of thyroid cancer from thyroid nodules utilizing a
next generation sequencing assay; ThyraMIR® for the diagnosis of
thyroid cancer from thyroid nodules utilizing a proprietary gene
expression assay; and RespriDX™ that differentiates lung cancer of
primary vs. metastatic origin. BarreGEN® for Barrett's
Esophagus, is currently being “soft launched” with key opinion
leaders as we continue to gather data on this assay that will
assist us in seeking favorable reimbursement as well as important
clinical information. Barrett's Esophagus is a rapidly growing
diagnosis that affects over three million people in the US and over
time can progress to esophageal cancer. The Company’s data base
includes data from over 45,000 patients who have been tested using
the Company’s current products, including over 15,000 molecular
tests for thyroid nodules. Interpace has been designated as one of
the top 20 companies for providing bioinformatics solutions.
Interpace’s mission is to provide personalized medicine
through molecular diagnostics, innovation and data to advance
patient care based on rigorous science. For more information,
please visit Interpace’s website
at www.interpacediagnostics.com
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance, competitive
and market conditions and future business decisions, all of which
are difficult or impossible to predict accurately and many of which
are beyond the Company's control. These statements also involve
known and unknown risks, uncertainties and other factors that may
cause the Company's actual results to be materially different from
those expressed or implied by any forward-looking statement. Known
and unknown risks, uncertainties and other factors include, but are
not limited to, the Company’s history of losses, the Company's
ability to adequately finance the business, the market's acceptance
of its molecular diagnostic tests, its ability to retain or secure
reimbursement, its ability to secure additional business and
generate higher profit margins through sales of its molecular
diagnostic tests, in-licensing or other means, projections of
future revenues, growth, gross profit and anticipated internal rate
of return on investments and its ability to maintain its NASDAQ
listing. Additionally, all forward-looking statements are subject
to the “Risk Factors” detailed from time to time in the Company's
SEC filings, including its Annual Report on Form 10-K for the
fiscal year ended December 31, 2017, filed on March 23, 2018,
Quarterly Reports on Form 10-Q and other SEC filings. Because
of these and other risks, uncertainties and assumptions, undue
reliance should not be placed on these forward-looking statements.
In addition, these statements speak only as of the date of this
press release and, except as may be required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
CONTACTS:
Interpace DiagnosticsInvestor Relations:
Joe Green – Edison Group(646) 653-7030jgreen@edisongroup.com
Andrew Gibson – Edison Group(646)
653-7719agibson@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024